Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 8/20 | 0.49 |
| ▸ | ACHE | P22303 | 8/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804690 | 0.93 | MAPT (0.59) | MAPTL3MBTL1BCHEACHEFAAH | |
| SCHEMBL16804696 | 0.91 | MAPT (0.58) | MAPTL3MBTL1BCHEACHEFAAH | |
| SCHEMBL16804697 | 0.88 | MTNR1A (0.49) | MAPTL3MBTL1BCHEACHEFAAH | |
| SCHEMBL936949 | 0.85 | L3MBTL1 (0.61) | MAPTL3MBTL1LTA4HCHRNB2CHRNB4 | |
| SCHEMBL16804700 | 0.85 | HTT (0.58) | MAPTL3MBTL1SIGMAR1CHRNB2CHRNB4 | |
| SCHEMBL10110750 | 0.83 | L3MBTL1 (0.60) | MAPTL3MBTL1MTNR1AMTNR1BHTT | |
| SCHEMBL16572084 | 0.80 | L3MBTL1 (0.69) | MAPTL3MBTL1BCHEHTT | |
| SCHEMBL16572083 | 0.80 | MAPT (0.60) | MAPTL3MBTL1BCHECHRNB2CHRNB4 | |
| SCHEMBL10110748 | 0.80 | L3MBTL1 (0.54) | MAPTL3MBTL1MTNR1AMTNR1BHTT | |
| SCHEMBL16572102 | 0.79 | MAPT (0.59) | MAPTL3MBTL1BCHECHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957238-B2 | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9586911-B2 | Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9102633-B2 | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MAPT 4487/4885L3MBTL1 4154/4885BCHE 866/4885 |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MAPT 4148/4885L3MBTL1 4397/4885BCHE 1717/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MAPT 4148/4885L3MBTL1 4397/4885BCHE 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.